Kombinasi Propranolol dan Digoksin Oral untuk Tatalaksana Paroxysmal Supraventricular Tachycardia (PSVT) di Fasilitas Layanan Primer
DOI:
https://doi.org/10.55175/cdk.v46i6.439Keywords:
Digoksin oral, fasilitas layanan primer, propanolol oral, PSVT, takikardia supraventrikuler paroksismalAbstract
Takikardia supraventrikuler paroksismal merupakan salah satu kegawatdaruratan jantung pada pasien dengan atau tanpa kelainan kardiovaskuler. Penanganan akut PSVT meliputi manuver vagal, kardioversi tersinkronisasi, dan terapi farmakologis. Kasus seorang wanita usia 41 tahun dengan takikardia supraventrikuler paroksismal berhasil dikonversi menjadi irama sinus dengan propranolol 40 mg oral dan digoksin 0,25 mg oral di fasilitas layanan primer.
Paroxysmal supraventricular tachycardia is a common cardiac emergency that can occur with or without prior cardiovascular abnormalities. Acute management of PSVT includes vagal maneuver, synchronized cardioversion, and pharmacological treatment. A 41 year-old female with paroxysmal supraventricular tachycardia was converted successfully to sinus rhythm with 40 mg oral propranolol plus 0.25 mg oral digoxin in a primary care setting.
Downloads
References
Olgin JE, Zipes DP. Supraventricular arrhythmias. In : Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, editors. Braunwald’s heart disease a textbook of cardiovascular medicine 11th ed. Philadelphia: Elsevier; 2019. pp.706-29
Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS Guideline for the management of adult patients with supraventricular tachycardia: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Circulation 2016;133;506-74.
Katritsis DG, Boriani G, Cosio FG, Hindricks G, Jais P, Josephson ME, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pasific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). Eurospace 2017;19:465-511
Issa ZF, Miller JM, Zipes DP. Approach to paroxysmal supraventricular tachycardias In: Issa ZF, Miller JM, Zipes DP, editors. Clinical arrhythmology and electrophysiology: A companion to Braunwald’s heart disease. Philadelphia:Elsevier; 2012. pp. 480-98
Porter MJ, Morton JB, Denman R. Lin AC, Tierney S, Santucci PA, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004;1:393–6
Link MS. Clinical practice. Evaluation and initial treatment of supraventricular tachycardia. N Engl J Med. 2012;367:1438-48
Gugneja M, El-Chami MF. Paroxysmal supraventricular tachycardia [Internet]. 2017. Available from: http://emedicine.medscape.com/article/156670
Wood KA, Drew BJ, Scheinman MM. Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol. 1997;79(2):145-9
Kosasih A, Sugiman T. Buku ajar kursus bantuan hidup jantung lanjut ACLS Indonesia. Jakarta: PERKI; 2018.
Lim SH, Anantharaman V, Teo WS, Goh PP, Tan ATH. Comparison of treatment of supraventricular tachycardia by Valsalva maneuver and carotid sinus massage. Ann Emerg Med.1998;31: 30-5
Wayne MA. Conversion of paroxysmal atrial tachycardia by facial immersion in ice water. JACEP. 1976;5:434–5
Yeh SJ, Lin FC, Chou YY, Hung JS, Wu D. Termination of paroxysmal supraventricular tachycardia with a single oral dose of diltiazem and propranolol. Circulation. 1985;71:104–9.
Alboni P, Tomasi C, Menozzi C, Bottoni N, Paparella N, Fuca G, et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol. 2001;37:548–53.
Campbell TJ, MacDonald PS. Digoxin in heart failure and cardiac arrhythmias. MJA. 2003; 179: 98-102
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
